The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease
Open Access
- 11 March 2021
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (2)
Abstract
The Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire was developed with substantial input from patients with idiopathic pulmonary fibrosis (IPF) to assess symptoms and health-related quality of life (HRQoL). Because IPF is the prototypical chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, we expanded applicability of the L-IPF by deleting the word “idiopathic”, creating the L-PF (Living with Pulmonary Fibrosis) questionnaire, and then assessed its relevance among patients with progressive fibrosing ILDs in one-to-one interviews.Patients in the USA and Germany with any progressive fibrosing ILD other than IPF were asked about their disease and symptoms, completed the 44-item L-PF questionnaire (comprising two modules that assess symptoms and impacts of disease) and then answered a series of debriefing questions. Interviews were recorded, transcribed and coded for qualitative content analysis.20 patients were interviewed, but time constraints meant not all were asked about all items. The most frequent diagnoses were rheumatoid arthritis-associated ILD (25%) and mixed connective tissue disease-associated ILD (20%). Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath (19 out of 20 patients), cough (19 out of 20) and fatigue (18 out of 20). Most patients endorsed impacts of progressive fibrosing ILD on activities of daily living, physical well-being, sleep, emotional well-being, and social aspects of their lives. Most patients had an overall positive impression of the Symptoms module and understood items as intended. All seven patients asked understood the items of the Impacts module.The L-PF contains concepts relevant and important to patients with progressive fibrosing ILD, and items are understood as intended.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 15 references indexed in Scilit:
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Validation of the IPF-specific version of St. George’s Respiratory QuestionnaireRespiratory Research, 2019
- Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseasesClinical Rheumatology, 2019
- Fibrosing interstitial lung diseases: knowns and unknownsEuropean Respiratory Review, 2019
- Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseasesEuropean Respiratory Review, 2018
- Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseasesEuropean Respiratory Review, 2018
- Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseBMJ Open Respiratory Research, 2017
- Content Validity of CASA-Q Cough Domains and UCSD-SOBQ for Use in Patients with Idiopathic Pulmonary FibrosisGlobal Journal of Health Science, 2013
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The SF-36 and SGRQ: Validity and first look at minimum important differences in IPFRespiratory Medicine, 2010